ReviewCNS neuroscience & therapeutics2008
A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.
Review in CNS neuroscience & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Dual-target mu opioid-dopamine DEuropean journal of medicinal chemistry · 2026Article
- Associative memory neurons are recruited in PFC-centered circuits to encode schizophrenia-like behavior by dopaminergic receptor-II.Molecular psychiatry · 2026Article
- Design, synthesis, drug-likeness, and molecular dynamics evaluations of monobrominated amathamide G analogs as potential ligands for D2-like dopamine receptors.In silico pharmacology · 2026Article
- Optogenetic Stimulation of Midbrain Dopamine Neurons Produces Striatal Serotonin Release.ACS chemical neuroscience · 2022Article
- Structure Activity Relationships for a Series of Eticlopride-Based Dopamine DJournal of medicinal chemistry · 2021Article
- Synthesis and In Vitro Evaluation of Novel Dopamine Receptor DBiomolecules · 2021Article
- Article
- Molecular Design in Synthetically Accessible Chemical Space via Deep Reinforcement Learning.ACS omega · 2020Article
- Neural bases for attenuation of morphine withdrawal by Heantos-4: role of l-tetrahydropalmatine.Scientific reports · 2020Article
- Effect of Dopamine DMolecular pharmaceutics · 2020Article
- Structure-based development of caged dopamine DScientific reports · 2020Article
- Identification and Functional Analysis of Long Non-coding RNAs in Autism Spectrum Disorders.Frontiers in genetics · 2020Article
- Neural Substrates of Dopamine D2 Receptor Modulated Executive Functions in the Monkey Prefrontal Cortex.Cerebral cortex (New York, N.Y. : 1991) · 2015Article
- Choice for response alternatives differing in reinforcement frequency in dopamine D2 receptor mutant and Swiss-Webster mice.Psychopharmacology · 2014Article
- Central manipulation of dopamine receptors attenuates the orexigenic action of ghrelin.Psychopharmacology · 2013Article
- Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration.Behavioural brain research · 2013Article
- Quantitative unit classification of ventral tegmental area neurons in vivo.Journal of neurophysiology · 2012Article
- Dopamine D(2) Antagonist-Induced Striatal Nur77 Expression Requires Activation of mGlu5 Receptors by Cortical Afferents.Frontiers in pharmacology · 2012Article
- Dopamine receptors and Parkinson's disease.International journal of medicinal chemistry · 2011Review
- Dopamine activity in the lateral anterior hypothalamus modulates AAS-induced aggression through D2 but not D5 receptors.Behavioral neuroscience · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Eticlopride is a substituted benzamide analog with high affinity and selectivity for dopamine (DA) D2-like receptors that was initially developed as a potential antipsychotic agent. A great deal of research has utilized this drug to better understand central DA receptor function, the role of D2-like receptors in behavior, and the influence of blockade of these receptors on several preclinical animal models. This review highlights research utilizing this drug and compares it to typical and atypical antipsychotics used clinically. First, we describe structure-activity relationships as it relates to binding at DA receptors and the consequences on behavior. This is followed by a discussion of several imaging strategies including the use of eticlopride for in vivo, in vitro, and ex vivo examination of DA D2-like receptor densities and function. Finally, we discuss the use of eticlopride in several behavioral models predictive of antipsychotic activity, extrapyramidal side effects (EPS), and learning and memory. While eticlopride is not used clinically, it remains a viable research tool for understanding DA receptor function and behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.